Evidence map›Paper›PMID 42797077›Full record

ReviewNutrients2026

Alginate Oligosaccharides in Lipid Metabolism: A Dual-Action Marine Prebiotic.

Jiaqi Liang, Ruibo Zhang, Meiling Song, Wanghua Bi, Quancai Li, Zhen Chen

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaqi LiangSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.ORCID 0009-0003-6713-2307
Ruibo ZhangSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Meiling SongSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Wanghua BiMarine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
Quancai LiMarine Biomedical Research Institute of Qingdao, Qingdao 266071, China.ORCID 0000-0001-8545-8384
Zhen ChenSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0001-5339-2499

Funding

Department of Science and Technology of Shandong Province 2022CXPT037Jiangsu University 5501290015
6 · The paper itself

Abstract

Alginate oligosaccharides (AOS) are degradation products of brown seaweed alginate, known as dietary bioactive components and used as health-beneficial nutrients. Unlike conventional prebiotics such as fructo-oligosaccharides, galacto-oligosaccharides, and xylo-oligosaccharides, AOS carry carboxyl groups and are negatively charged at physiological pH. This narrative review uses charge as an organizing framework for understanding their lipid-regulating effects. Neutral oligosaccharides act mainly through gut microbial fermentation, whereas charged oligosaccharides can also act on host cells directly, although charge and backbone structure cannot be fully separated in the available studies. The gut-dependent actions of AOS (microbiota modulation, short-chain fatty acid production, bile acid metabolism, and barrier protection) and the direct actions supported mainly by in vitro evidence or parenteral administration in animals, including AMP-activated protein kinase (AMPK) activation, brown adipose tissue thermogenesis, and candidate receptor-mediated effects, are discussed, although the systemic exposure achievable after oral intake remains to be established. The beneficial functions of AOS depend on structural parameters such as degree of polymerization, M/G ratio, and terminal unsaturation; the AOS product approved in China in 2026 is produced by acid hydrolysis, and its relationship to the more active unsaturated forms remains unresolved. Structurally defined AOS are to be developed for nutritional supplementation and as potential candidates for clinical evaluation.

Indexed as

AlginatesLipid MetabolismOligosaccharidesPrebioticsAnimalsGastrointestinal MicrobiomeHumansAlginatesOligosaccharidesPrebioticscharged oligosaccharidesdyslipidemiagut microbiotametabolic disordersmetabolic dysfunction-associated steatotic liver diseaseprebioticsshort-chain fatty acids

Identifiers

PMID42797077
PMCPMC13610710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.